Met in Urological Cancers

Met in Urological Cancers

Met is a tyrosine kinase receptor that is considered to be a proto-oncogene. The hepatocyte growth factor (HGF)-Met signaling system plays an important role in tumor growth, invasion, and metastasis in many types of malignancies. Furthermore, Met expression has been reported to be a useful predicti...

Full description

Bibliographic Details
Main Authors:	Yasuyoshi Miyata, Akihiro Asai, Kensuke Mitsunari, Tomohiro Matsuo, Kojiro Ohba, Yasushi Mochizuki, Hideki Sakai
Format:	Article
Language:	English
Published:	MDPI AG 2014-12-01
Series:	Cancers
Subjects:	Met prostate cancer renal cell carcinoma urothelial cancer pathological features survival target therapy
Online Access:	http://www.mdpi.com/2072-6694/6/4/2387

Similar Items

Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
by: Pengxiao Su, et al.
Published: (2023-03-01)

A Review of Oxidative Stress and Urinary Dysfunction Caused by Bladder Outlet Obstruction and Treatments Using Antioxidants
by: Yasuyoshi Miyata, et al.
Published: (2019-05-01)

Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers
by: Shoichiro Mukai, et al.
Published: (2020-04-01)

Editorial: Insights in urologic oncology, volume I
by: Olivia Krivitsky, et al.
Published: (2023-08-01)

Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators
by: Tsutomu Yuno, et al.
Published: (2020-10-01)

Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies
by: Lucas Nogueira, et al.
Published: (2020-11-01)

MET Expression Level in Lung Adenocarcinoma Loosely Correlates with <i>MET</i> Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome
by: Wei Yin, et al.
Published: (2022-05-01)

STAT3 and Its Pathways’ Dysregulation—Underestimated Role in Urological Tumors
by: Maciej Golus, et al.
Published: (2022-09-01)

Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
by: Brigida Anna Maiorano, et al.
Published: (2021-06-01)

Pathological Significance of Macrophages in Erectile Dysfunction Including Peyronie’s Disease
by: Yasuyoshi Miyata, et al.
Published: (2021-11-01)

Oral Intake of Royal Jelly Has Protective Effects Against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial
by: Kyohei Araki, et al.
Published: (2018-12-01)

Pharmacological Effects and Potential Clinical Usefulness of Polyphenols in Benign Prostatic Hyperplasia
by: Kensuke Mitsunari, et al.
Published: (2021-01-01)

Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer
by: Yasuyoshi Miyata, et al.
Published: (2020-12-01)

Efficacy of salt reduction for managing overactive bladder symptoms: a prospective study in patients with excessive daily salt intake
by: Tomohiro Matsuo, et al.
Published: (2021-02-01)

Relationship between Urinary Calcium Excretion and Lower Urinary Tract Symptoms
by: Tomohiro Matsuo, et al.
Published: (2022-03-01)

Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder
by: Hidenori Ito, et al.
Published: (2022-06-01)

15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysisResearch in context
by: Mahati Paravathaneni, et al.
Published: (2024-02-01)

Human Endogenous Retroviruses: Friends and Foes in Urology Clinics
by: Sun-Kyung Lee, et al.
Published: (2022-12-01)

Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607
by: Dai Yao, et al.
Published: (2012-05-01)

Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review
by: Achille Aveta, et al.
Published: (2023-06-01)

Urothelial-Type adenocarcinoma of the prostate mimicking metastatic colorectal adenocarcinoma
by: Brian P. Adley, et al.
Published: (2006-12-01)

Predictive efficacy of the 2014 International Society of Urological Pathology Gleason grading system in initially diagnosed metastatic prostate cancer
by: Guang-Xi Sun, et al.
Published: (2017-01-01)

Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder
by: Young H. Lee, et al.
Published: (2014-11-01)

High expression of HuR in cytoplasm, but not nuclei, is associated with malignant aggressiveness and prognosis in bladder cancer.
by: Yasuyoshi Miyata, et al.
Published: (2013-01-01)

Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells
by: Sun Tae Hwang, et al.
Published: (2020-03-01)

Molecular Mechanisms of the Anti-Cancer Effects of Isothiocyanates from Cruciferous Vegetables in Bladder Cancer
by: Tomhiro Mastuo, et al.
Published: (2020-01-01)

Editorial: Biomarkers in genitourinary cancers: Volume II
by: Takeshi Yuasa
Published: (2022-10-01)

MET fusions are targetable genomic variants in the treatment of advanced malignancies
by: Dantong Sun, et al.
Published: (2024-01-01)

Nomograms in Urologic Oncology: Lights and Shadows
by: Alessandro Morlacco, et al.
Published: (2021-03-01)

Characteristics and survival of primary urothelial carcinoma of the prostate: A multi-center retrospective study of 18 cases
by: Junjie Ji, et al.
Published: (2024-01-01)

Anticancer Effects of Green Tea and the Underlying Molecular Mechanisms in Bladder Cancer
by: Yasuyoshi Miyata, et al.
Published: (2018-08-01)

Pathological and Pharmacological Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds, Natural Products, and Photosensitizers
by: Yasuyoshi Miyata, et al.
Published: (2020-11-01)

Clinical and biological relevance of the transcriptomic‐based prostate cancer metastasis subtypes MetA‐C
by: Elin Thysell, et al.
Published: (2022-02-01)

EUROPEAN SECTION OF ONCOLOGICAL UROLOGY (ESOU): NEW DATA IN 2017
by: S. A. Reva
Published: (2018-03-01)

Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. <i>Medicines</i>, 2019, <i>6</i>, 2
by: Kyohei Araki, et al.
Published: (2020-11-01)

A pilot study to assess the safety and usefulness of combined transurethral endoscopic mucosal resection and en-bloc resection for non-muscle invasive bladder cancer
by: Yasushi Hayashida, et al.
Published: (2019-06-01)

Pathological Characteristics of Periodontal Disease in Patients with Chronic Kidney Disease and Kidney Transplantation
by: Mineaki Kitamura, et al.
Published: (2019-07-01)

An Overview of siRNA Delivery Strategies for Urological Cancers
by: Nadia Halib, et al.
Published: (2022-03-01)

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC
by: Guang-Ling Jie, et al.
Published: (2023-01-01)

Use of immunotherapy in clinical management of genitourinary cancers – a review
by: Nataliya Mar, et al.
Published: (2022-01-01)